Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Radius Raises $91 Million, Moves Toward Public Listing

This article was originally published in Start Up

Executive Summary

Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.

You may also be interested in...

After Canceling IPO, Radius May Tap Institutional Investors

With its IPO withdrawn, osteoporosis drug developer Radius Therapeutics is likely to seek funding from institutional backers. The company has just enough cash to last it through the first quarter, with big costs for a Phase III trial in the works.

Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round

Plus news on recent financings by Visterra, AbbVie, Pearl Therapeutics and Auspex.

Wellcome Trust Launches £200 Million Fund For Diverse Health Care Investments

The U.K.’s largest charitable foundation for biomedical research is the sole investor in a new fund that will target start-ups as well as later-stage growth opportunities across the health care spectrum.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts